Abstract
Depression is a serious psychiatric illness that affects millions of people worldwide. Weeks of antidepressant therapy are required to relieve depressive symptoms, and new drugs are still being extensively researched. The latest studies have shown that in depression, there is an imbalance between the main excitatory (glutamatergic) and inhibitory (GABAergic) systems. Administration of antagonists of the glutamatergic system, including zinc, has shown an antidepressant effect in preclinical as well as clinical studies. Zinc inhibits the NMDA receptor via its binding site located on one of its subunits. This is thought to be the main mechanism explaining the antidepressant properties of zinc. In the present review, a link between zinc and the glutamatergic system is discussed in the context of depressive disorder.
Current Neuropharmacology
Title:Zinc in the Glutamatergic Theory of Depression
Volume: 13 Issue: 4
Author(s): Katarzyna Mlyniec
Affiliation:
Keywords: Depression, GABA, glutamate, GPR39, NMDA, zinc.
Abstract: Depression is a serious psychiatric illness that affects millions of people worldwide. Weeks of antidepressant therapy are required to relieve depressive symptoms, and new drugs are still being extensively researched. The latest studies have shown that in depression, there is an imbalance between the main excitatory (glutamatergic) and inhibitory (GABAergic) systems. Administration of antagonists of the glutamatergic system, including zinc, has shown an antidepressant effect in preclinical as well as clinical studies. Zinc inhibits the NMDA receptor via its binding site located on one of its subunits. This is thought to be the main mechanism explaining the antidepressant properties of zinc. In the present review, a link between zinc and the glutamatergic system is discussed in the context of depressive disorder.
Export Options
About this article
Cite this article as:
Mlyniec Katarzyna, Zinc in the Glutamatergic Theory of Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X13666150115220617
DOI https://dx.doi.org/10.2174/1570159X13666150115220617 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Current Topics in Medicinal Chemistry New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders
CNS & Neurological Disorders - Drug Targets Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Anti-Inflammatory Drug Targeting in Asthma. Should Inhaled Corticosteroids Reach the Small Airways?
Current Drug Therapy Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy Triazol-phenyl Antipyretic Derivatives Inhibit mPGES-1 mRNA Levels in LPS-Induced RAW 264.7 Macrophage Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Effect of Nitric Oxide Synthase Inhibition on Body Temperature Control During Endotoxemic Shock
Current Enzyme Inhibition Inhibition of Fatty Acid Synthase by Polyphenols
Current Medicinal Chemistry